NeuroKaire Overview
NeuroKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The NeuroKaire test predicts the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Cumulative Funding Raised Over Time ($)
$10.0MJun 2024
$11.2MOct 2018
$21.1MSep 2021
Latest News
growth-positive
Israeli startup NeuroKaire launches world’s first blood test to personalize depression treatment | CTech
NeuroKaire, formerly known as Genetika+, has launched BrightKaire, a groundbreaking test that uses AI and stem-cell technology to personalize antidepressant treatment for patients with major depressive disorder (MDD). This innovation, which has received regulatory approval in the U.S., allows for a more accurate and faster determination of effective medication, potentially reducing the trial-and-error period from years to weeks. The company has raised $25 million from venture capital funds and secured additional grants from the European Union. BrightKaire is available in the U.S. and Israel, with tests conducted in the U.S. NeuroKaires approach represents a significant advancement in personalized psychiatry, offering hope for more effective treatment of depression.
Product StageInvestmentCustomersPartners
growth-positive
/PRNewswire/ -- NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, has successfully secured $10...
NeuroKaire, a biotechnology company specializing in precision medicine for psychiatry and neurology, has secured $10 million in funding to advance its clinical test for identifying drug efficacy in depression patients. The funding round was led by GreyBird Ventures, with participation from Meron Capital and Jumpspeed Ventures. This investment will enable NeuroKaire to scale operations, expand its team, and deepen research and development efforts. The company aims to enhance its pharmaceutical partnerships and drive innovation in drug discovery and development. NeuroKaires innovative test provides insights into brain function and drug response, helping clinicians identify the optimal antidepressant for patients. The company is poised to transform treatment paradigms in depression and improve the efficiency of new drug development.
InvestmentPartnersExpand
growth-positive
Clexio and Genetika+ announce partnership using proprietary antidepressant screening platform
Clexio and Genetika+ are partnering to screen and characterize Clexios antidepressant pipeline using Genetika+s iPSC-derived neurons platform. This partnership allows for the assessment of the functional effects of drugs directly on human neurons, enabling a readout of the antidepressant effect of a candidate drug and the characterization of a compound with respect to its effect on different depression subpopulations. The collaboration aims to contribute to the advancement of personalized medicine for psychiatry. Clexio is a CNS-first clinical stage pharmaceutical company dedicated to developing novel therapies for neurological and psychiatric conditions. Genetika+ is developing personalized medicine solutions for psychiatric and neurological diseases.
Partners
growth-positive
Genetika+ obtains CE-IVD mark for NeuroKaire blood test
Genetika+ has obtained a CE-IVD mark for its new blood test, NeuroKaire, which aims to optimize treatment for depression. The AI-powered tool helps physicians determine the optimal antidepressant treatment required for major depressive disorder (MDD) patients. The test has been developed using data collected from MDD patients and leverages advanced AI and machine learning approaches. A multi-site study showed high accuracy in predicting drug response in MDD patients, validating NeuroKaires efficacy. Genetika+ plans to collaborate with hospitals and physicians to launch the tool in regular clinical practice. The CE-IVD mark demonstrates the accuracy and efficacy of NeuroKaire and facilitates its adoption in the European market. MDD is estimated to affect over 300 million people globally.
Customers
growth-positive
Genetika+ Announces CE Mark for NeuroKaire™ its AI-powered Tool to Optimize Depression Treatment
Genetika+ has announced the CE-IVD mark for NeuroKaire, a blood test that predicts drug response in patients with major depressive disorder (MDD). The test is designed to assist physicians in prescribing the optimal antidepressant treatment for MDD patients. Genetika+ is partnering with physicians and hospitals to implement the tool in routine clinical practice. The NeuroKaire test combines AI-driven biomarkers, pharmacogenetics, and clinical data to provide accurate predictions of drug response. The CE mark follows successful results from a multi-site study, validating the efficacy of NeuroKaire. MDD affects over 300 million people globally, and there is a significant unmet need for a product like NeuroKaire to improve treatment outcomes and reduce healthcare costs associated with suboptimal disease management.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $25.27M |
| Last funding | $10M |
| Stage | A |
| Rounds | 7 |
| Investors | 7 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.neurokaire.com |
| Careers | Careers page |
Locations
Yigal Alon St 126, Tel Aviv-Yafo, Israel
78 John Miller Way, Kearny, NJ 07032, USA
Photos & Videos
1 item(s)
NeuroKaire Business
Business models
B2B2C, B2B
Product stage
Beta
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision SupportTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticalsCore Technology
Artificial IntelligenceMachine LearningTags (20)
clinical-trialsneurologygenetic-engineeringpharma-companiesdeep-learningmental-healthmachine-learningdigital-healthcaremedicationdoctorspersonalizationtestingartificial-intelligenceclinicshealthcare-providerspatientsneurosciencehospitalspsychiatrydecision-supportSolutions
{"title":"Healthcare","description":"NeuroKaire offers an AI-powered digital platform for clinicians to remotely monitor, manage, and provide personalized care for patients with neurological conditions, such as Parkinson's disease, by tracking symptoms, medication adherence, and delivering objective insights.","items":[{"name":"Revenue Growth","value":3,"titleTooltip":"Revenue Growth & Profitability","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Operational Efficiency","value":4,"titleTooltip":"Operational Excellence & Efficiency","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Customer Acquisition","value":4,"titleTooltip":"Customer Acquisition, Satisfaction & Loyalty","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Risk Mitigation","value":3,"titleTooltip":"Risk Mitigation & Business Resilience","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Talent Development","value":3,"titleTooltip":"Talent Development & Employee Empowerment","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Agility & Innovation","value":4,"titleTooltip":"Strategic Agility & Innovation","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}}]}
{"title":"Biopharma","description":"NeuroKaire's StemifAi is an AI-driven platform designed to accelerate drug discovery and development for neurological disorders, optimizing R&D processes, improving clinical trial success rates, and reducing costs.","items":[{"name":"Revenue Growth","value":4,"titleTooltip":"Revenue Growth & Profitability","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Operational Efficiency","value":5,"titleTooltip":"Operational Excellence & Efficiency","meterTooltip":{"title":"Disruptive / Paradigm-Shifting","content":"Revolutionary, industry-leading change that sets new benchmarks and norms."}},{"name":"Customer Acquisition","value":3,"titleTooltip":"Customer Acquisition, Satisfaction & Loyalty","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Risk Mitigation","value":4,"titleTooltip":"Risk Mitigation & Business Resilience","meterTooltip":{"title":"Transformative / Strategic","content":"Fundamental, high-value enhancement with far-reaching strategic importance."}},{"name":"Talent Development","value":3,"titleTooltip":"Talent Development & Employee Empowerment","meterTooltip":{"title":"Substantial / Core","content":"Clear, significant contribution; broad, tangible gains."}},{"name":"Agility & Innovation","value":5,"titleTooltip":"Strategic Agility & Innovation","meterTooltip":{"title":"Disruptive / Paradigm-Shifting","content":"Revolutionary, industry-leading change that sets new benchmarks and norms."}}]}
Use Cases
NeuroKaireStemifAiGeographic Markets
United StatesEuropeNeuroKaire Financials
$25.27M
Total funding
Undisclosed
Capital raised
$10M
Last funding
A
Funding stage
7
Total rounds
7
Investors
Cumulative Funding Raised Over Time ($)
$10.0MJun 2024
$11.2MOct 2018
$21.1MSep 2021
Private Equity Funding
A Round
Jun 2024
$10M
GreyBird Ventures (Lead)
,
Jumpspeed Ventures, Meron Capital
A Round
Sep 2021
$10M
GreyBird Ventures (Lead)
,
Michael Zeisser, Howard Morgan, Meron Capital, Jumpspeed Ventures, Sapir Venture Partners
Seed
Oct 2018
$1.15M
Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan, Meron Capital, Israel Innovation Authority
Non-Equity Funding
GrantEvent
Sep 2022
$2.5M
European Union’s EIC Fund
GrantEvent
Jul 2020
$1M
Israel Innovation Authority
GrantEvent
Mar 2019
$580K
Israel Innovation Authority
GrantEvent
Nov 2018
$40K
NeuroKaire Lifecycle
Cumulative Funding Raised Over Time
$10.0MJun 2024
$11.2MOct 2018
$21.1MSep 2021
All Events
A Round
Jun 2024
$10M
GreyBird Ventures (Lead)
,
Jumpspeed Ventures, Meron Capital
A Round
Sep 2021
$10M
GreyBird Ventures (Lead)
,
Michael Zeisser, Howard Morgan, Meron Capital, Jumpspeed Ventures, Sapir Venture Partners
Seed
Oct 2018
$1.15M
Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan, Meron Capital, Israel Innovation Authority
GrantEvent
Sep 2022
$2.5M
European Union’s EIC Fund
GrantEvent
Jul 2020
$1M
Israel Innovation Authority
GrantEvent
Mar 2019
$580K
Israel Innovation Authority
GrantEvent
Nov 2018
$40K
NeuroKaire News
12 articles
growth-positive
Israeli startup NeuroKaire launches world’s first blood test to personalize depression treatment | CTech
NeuroKaire, formerly known as Genetika+, has launched BrightKaire, a groundbreaking test that uses AI and stem-cell technology to personalize antidepressant treatment for patients with major depressive disorder (MDD). This innovation, which has received regulatory approval in the U.S., allows for a more accurate and faster determination of effective medication, potentially reducing the trial-and-error period from years to weeks. The company has raised $25 million from venture capital funds and secured additional grants from the European Union. BrightKaire is available in the U.S. and Israel, with tests conducted in the U.S. NeuroKaires approach represents a significant advancement in personalized psychiatry, offering hope for more effective treatment of depression.
Product StageInvestmentCustomersPartners
growth-positive
/PRNewswire/ -- NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, has successfully secured $10...
NeuroKaire, a biotechnology company specializing in precision medicine for psychiatry and neurology, has secured $10 million in funding to advance its clinical test for identifying drug efficacy in depression patients. The funding round was led by GreyBird Ventures, with participation from Meron Capital and Jumpspeed Ventures. This investment will enable NeuroKaire to scale operations, expand its team, and deepen research and development efforts. The company aims to enhance its pharmaceutical partnerships and drive innovation in drug discovery and development. NeuroKaires innovative test provides insights into brain function and drug response, helping clinicians identify the optimal antidepressant for patients. The company is poised to transform treatment paradigms in depression and improve the efficiency of new drug development.
InvestmentPartnersExpand
growth-positive
Clexio and Genetika+ announce partnership using proprietary antidepressant screening platform
Clexio and Genetika+ are partnering to screen and characterize Clexios antidepressant pipeline using Genetika+s iPSC-derived neurons platform. This partnership allows for the assessment of the functional effects of drugs directly on human neurons, enabling a readout of the antidepressant effect of a candidate drug and the characterization of a compound with respect to its effect on different depression subpopulations. The collaboration aims to contribute to the advancement of personalized medicine for psychiatry. Clexio is a CNS-first clinical stage pharmaceutical company dedicated to developing novel therapies for neurological and psychiatric conditions. Genetika+ is developing personalized medicine solutions for psychiatric and neurological diseases.
Partners
growth-positive
Genetika+ obtains CE-IVD mark for NeuroKaire blood test
Genetika+ has obtained a CE-IVD mark for its new blood test, NeuroKaire, which aims to optimize treatment for depression. The AI-powered tool helps physicians determine the optimal antidepressant treatment required for major depressive disorder (MDD) patients. The test has been developed using data collected from MDD patients and leverages advanced AI and machine learning approaches. A multi-site study showed high accuracy in predicting drug response in MDD patients, validating NeuroKaires efficacy. Genetika+ plans to collaborate with hospitals and physicians to launch the tool in regular clinical practice. The CE-IVD mark demonstrates the accuracy and efficacy of NeuroKaire and facilitates its adoption in the European market. MDD is estimated to affect over 300 million people globally.
Customers
growth-positive
Genetika+ Announces CE Mark for NeuroKaire™ its AI-powered Tool to Optimize Depression Treatment
Genetika+ has announced the CE-IVD mark for NeuroKaire, a blood test that predicts drug response in patients with major depressive disorder (MDD). The test is designed to assist physicians in prescribing the optimal antidepressant treatment for MDD patients. Genetika+ is partnering with physicians and hospitals to implement the tool in routine clinical practice. The NeuroKaire test combines AI-driven biomarkers, pharmacogenetics, and clinical data to provide accurate predictions of drug response. The CE mark follows successful results from a multi-site study, validating the efficacy of NeuroKaire. MDD affects over 300 million people globally, and there is a significant unmet need for a product like NeuroKaire to improve treatment outcomes and reduce healthcare costs associated with suboptimal disease management.
Customers
Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
growth-positive
Genetika+ - A Pioneer in Personalized Medicine for Psychiatry - Raises $10 Million in an Oversubscribed Series A
Genetika+ has closed a $10 million Series A funding round led by GreyBird Ventures to develop personalized medicine solutions for psychiatric and neurological diseases. The companys lead solution personalizes antidepressant treatment for each patient using its Brain-in-a-Dish technology. The funding will be used to accelerate the companys next phase, including expanded clinical trials, increased manufacturing capabilities, and establishment of a clinical lab in Boston. Genetika+ plans to hire for multiple positions over the next 12 months to support research and business development activities. Depression affects over 300 million people worldwide, and Genetika+ aims to provide a more effective and personalized approach to medication selection for depression patients.
InvestmentExpand
growth-positive
Genetika+: Combating Depression Talia Cohen Solal, CEO & Co-founder, Genetika+
The article features an interview with Talia Cohen Solal, the CEO & Co-Founder of Genetika+, a biotech start-up specializing in personalized medicine for major depression. Genetika+ uses biological data, genetic testing, and medical history to develop personalized depression treatments for patients. The company aims to eliminate the trial-and-error component of depression treatment by predicting which medication will work for each individual patient. Talia discusses her journey from academia to entrepreneurship, the challenges faced in the industry, and her passion for mental health. The article highlights the potential of healthcare technology to revolutionize personalized and targeted treatments. Talia also mentions the need for more resources and faster development of medical treatments. The impact on the company is growth-positive, as Genetika+ is advancing treatment in the mental health space.
Customers
Interview with Talia from Genetika+ - Network & Chill
growth-positive
Avon Products, Inc. Reveals Winner of Women Startup Competition - Direct Selling News
Genetika+ has won Avons Women Startup Competition 2019 with their cutting edge technology for determining the best drug to treat depression for each patient. The start-up from Jerusalem was crowned the winner during the final event in London. The competition brought together nine winners of the local semi-finals and three top start-ups from an online beauty accelerator program. The winners had the opportunity to meet with investors and Avon executives to help grow their business. The judging panel included investors and executives from Avon and Mintel. The competition aims to foster entrepreneurialism among women and encourage innovation that benefits society.
PartnersInvestment
growth-positive
https://www.jpost.com/Opinion/Hillels-Tech-Corner-Impact-at-its-best-589285
Genetika+ is an Israeli company developing a personalized test to help physicians choose the right drug for each patient suffering from depression. By combining a patients genetic background, patient history, and cell-based screening platform, Genetika+ aims to provide a reliable and accurate prediction of the optimal drug. The company has raised $1.4 million in funding and is conducting a retrospective clinical trial to demonstrate patient outcomes. Genetika+ plans to enter the market in 2021. The founders, Dr. Daphna Laifenfeld and Dr. Talia Cohen Solal, have impressive backgrounds in neuroscience and genetics. They are dedicated to improving the lives of those suffering from major depression and other mental illnesses.
CustomersPartnersInvestment
MassChallenge Israel Awards 500,000 ILS in Cash Prizes to Top Startups in Boston
NeuroKaire Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 46 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
NeuroKaire Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 515897205 |
| Crunchbase | genetika |
| Phone | +97253219656 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2025-09-10T00:00:00.000Z |
| Created | 2018-07-10T00:00:00.000Z |
| Claimed | Yes |